Study Summary
This trial is testing whether selumetinib is as effective as the standard treatment (carboplatin and vincristine) for low-grade glioma. It will also compare the side effects of the two treatments.
- Low Grade Glioma
- Metastatic Low Grade Glioma
- Low Grade Astrocytoma
- Metastatic Low Grade Astrocytoma
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 7 Secondary · Reporting Duration: Up to 10 years
Trial Safety
Safety Progress
Side Effects for
Trial Design
2 Treatment Groups
Arm I (vincristine sulfate, carboplatin)
1 of 2
Arm II (selumetinib sulfate)
1 of 2
Active Control
Experimental Treatment
220 Total Participants · 2 Treatment Groups
Primary Treatment: Selumetinib Sulfate · No Placebo Group · Phase 3
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 2 - 21 · All Participants · 28 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:- Arnold, Antje, Fausto Rodriguez, Charles G Eberhart, and Eric H Raabe. 2020. “Response to Letter to the Editor: “all Models Are Wrong; Some Models Are Useful””. Neuro-oncology. Oxford University Press (OUP). doi:10.1093/neuonc/noaa137.
- Bergqvist, Christina, and Pierre Wolkenstein. 2020. “MEK Inhibitors in Rasopathies”. Current Opinion in Oncology. Ovid Technologies (Wolters Kluwer Health). doi:10.1097/cco.0000000000000711.
- Arnold A, Rodriguez F, Eberhart CG, Raabe EH. Response to letter to the editor: "All models are wrong; some models are useful". Neuro Oncol. 2020 Sep 29;22(9):1406-1407. doi: 10.1093/neuonc/noaa137. No abstract available.
- Bergqvist C, Wolkenstein P. MEK inhibitors in RASopathies. Curr Opin Oncol. 2021 Mar 1;33(2):110-119. doi: 10.1097/CCO.0000000000000711.
- 2020. "A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04166409.
Frequently Asked Questions
Does this experiment only test on individuals below a certain age?
"This trial is open to anyone who falls in the 2-21 age bracket." - Anonymous Online Contributor
How can I sign up for this opportunity to test a new treatment?
"Children aged 2-21 who have been diagnosed with astrocytoma are eligible for this clinical trial. Currently, the research team is looking to recruit approximately 220 patients." - Anonymous Online Contributor
What are the harmful side effects of Selumetinib Sulfate?
"Selumetinib Sulfate is rated as a 3 in terms of safety by our team at Power. This is due to the fact that this drug has completed Phase 3 trials, thus there is some data supporting both efficacy and safety." - Anonymous Online Contributor
In how many different settings is this research being conducted?
"100 patients are needed for this clinical trial, which is being conducted at Ascension Saint Vincent Indianapolis Hospital in Indianapolis, University of Iowa/Holden Comprehensive Cancer Center in Iowa City, Cedars Sinai Medical Center in Los Angeles, and 100 other locations." - Anonymous Online Contributor
Are there any patients presently enrolled in this clinical trial?
"Yes, according to the latest information on clinicaltrials.gov, this study is still recruiting patients. It was first posted on 1/3/2020, and the most recent update was on 11/8/2022. The trial needs 220 more participants across 100 locations." - Anonymous Online Contributor
What are the most similar medical studies to Selumetinib Sulfate?
"Selumetinib sulfate was first studied in 2001 at the UCSF Helen Diller Family Comprehensive Cancer Center. Over 1500 studies have been completed thus far, with nearly 1000 more currently underway--a large number of which are based out of Indianapolis, Indiana." - Anonymous Online Contributor
What illnesses does Selumetinib Sulfate help to alleviate?
"While often used to treat advanced sarcoma, selumetinib sulfate can also be given as initial treatment, or to patients with acquired immunodeficiency syndrome or advanced thymoma." - Anonymous Online Contributor
How many people are involved in this clinical trial?
"The data on clinicaltrials.gov does indeed show that this study is recruiting participants at the moment. The trial was first posted on January 3rd, 2020 and was most recently updated on November 8th, 2022. Currently, the study is looking for 220 participants across 100 different locations." - Anonymous Online Contributor